NCT02132130 - Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 23, 2014

Primary Completion Date

December 9, 2019

Study Completion Date

December 9, 2019

Conditions

Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss

Interventions

DRUG

CGF166

CGF166 is a recombinant adenovirus 5 (Ad5) vector containing the human Atonal transcription factor (Hath1) cDNA for administration via intra-labyrinthine infusion

Trial Locations (4)

10032

Novartis Investigative Site, New York

21287

Novartis Investigative Site, Baltimore

66160

Novartis Investigative Site, Kansas City

97239

Novartis Investigative Site, Portland